Tag Archives: RARE

Top 10 High Tech Stocks To Own Right Now

A relative calm in global markets is at risk of ending abruptly as U.S. traders return from a market holiday to the sight of Italy’s government in full-blown political crisis.

Populist parties called for fresh elections after Italy’s president refused to endorse their choice of finance minister and appointed Carlo Cottarelli, a former International Monetary Fund official, as prime minister instead.

The political impasse in the third-largest euro-zone economy has sent yields on Italian two-year government bonds up by a whopping 202.4 basis points this month — the first monthly jump of over 100 basis points since May 2012, when Europe was enmeshed in the debt crisis that triggered existential questions about the single currency. While U.S. Treasury yields slipped some in Tuesday trading, broad measures of volatility remain a fraction of February highs.

#lazy-img-328105134:before{padding-top:56.25%;}

"The lack of an obvious solution to this impasse is troubling, especially given the size of Italy’s economy and debt stock," Morgan Stanley analysts including Andrew Sheets wrote in a note dated May 28. "Yet given the worry it’s causing, it’s notable what hasn’t moved."

Top 10 High Tech Stocks To Own Right Now: InterOil Corporation(IOC)

Advisors’ Opinion:

  • [By Shane Hupp]

    I/O Coin (CURRENCY:IOC) traded 26.1% higher against the US dollar during the one day period ending at 22:00 PM E.T. on August 17th. Over the last seven days, I/O Coin has traded up 50% against the US dollar. One I/O Coin coin can now be purchased for $0.39 or 0.00005901 BTC on exchanges. I/O Coin has a market capitalization of $6.55 million and approximately $14,268.00 worth of I/O Coin was traded on exchanges in the last day.

  • [By Stephan Byrd]

    Media headlines about InterOil (NYSE:IOC) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. InterOil earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news articles about the oil and gas company an impact score of 45.5148763796823 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Top 10 High Tech Stocks To Own Right Now: Koss Corporation(KOSS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Loxo Oncology, Inc. (NASDAQ: LOXO) rose 17.1 percent to $163.30 in pre-market trading as the company disclosed that LOXO-292 Phase 1 trial abstract was selected for 'Best of ASCO'.
    CytomX Therapeutics, Inc. (NASDAQ: CTMX) rose 11.5 percent to $27.15 in pre-market trading after the company announced presentations at the 2018 ASCO Annual Meeting.
    Check-Cap Ltd. (NASDAQ: CHEK) rose 12.3 percent to $5.47 in pre-market trading after reporting narrower-than-expected Q1 loss.
    Flotek Industries, Inc. (NYSE: FTK) shares rose 7.1 percent to $3.62 in the pre-market trading session.
    Baozun Inc. (NASDAQ: BZUN) shares rose 5.8 percent to $47.65 in pre-market trading after reporting Q1 results.
    World Wrestling Entertainment, Inc. (NYSE: WWE) rose 5.5 percent to $46.00 in pre-market trading.
    Williams Partners L.P. (NYSE: WPZ) rose 5.3 percent to $40.50 in pre-market trading after The Williams Companies, Inc. (NYSE: WMB) announced agreement to acquire all public equity of Williams Partners in a $10.5 billion deal.
    Koss Corporation (NASDAQ: KOSS) shares rose 4.6 percent to $2.72 in pre-market trading after surging 12.55 percent on Wednesday.
    Enphase Energy, Inc. (NASDAQ: ENPH) rose 4.5 percent to $5.85 in pre-market trading after gaining 5.66 percent on Wednesday.
    Farmer Bros. Co. (NASDAQ: FARM) rose 4.1 percent to $27 in pre-market trading after climbing 7.90 percent on Wednesday.
    Kosmos Energy Ltd. (NYSE: KOS) rose 4 percent to $7.70 in pre-market trading.

     

  • [By Lisa Levin] Gainers
    Stellar Biotechnologies, Inc. (NASDAQ: SBOT) rose 32 percent to $2.89 in pre-market trading after the company disclosed that it achieved robust viral clearance for its manufacturing process.
    Babcock & Wilcox Enterprises, Inc. (NYSE: BW) rose 17.7 percent to $3.03 in pre-market trading after an amended 13D filing from Steel Partners Holdings shows a raised stake in the company from 6.99 million shares to 29.98 million shares, or a 17.8 percent stake.
    AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) shares rose 12.7 percent to $3.55 in pre-market trading after the company announced the FDA acceptance of NDA for DSUVIA.
    Williams-Sonoma, Inc. (NYSE: WSM) shares rose 11.7 percent to $54.95 in pre-market trading. after the company reported stronger-than-expected results for its first quarter. The company also raised its FY18 earnings and sales guidance.
    Bilibili Inc. (NASDAQ: BILI) shares rose 9.3 percent to $13.59 in pre-market trading after announcing Q1 results.
    Stein Mart, Inc. (NASDAQ: SMRT) rose 8.1 percent to $3.46 in pre-market trading after reporting strong Q1 earnings.
    Universal Corporation (NYSE: UVV) rose 8.1 percent to $52.35 in pre-market trading after reporting fiscal Q4 results.
    Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) rose 8.1 percent to $5.65 in pre-market trading after gaining 6.30 percent on Wednesday.
    CEL-SCI Corporation (NYSE: CVM) rose 6.1 percent to $3.30 in pre-market trading after climbing 9.51 percent on Wednesday.
    TransEnterix, Inc. (NYSE: TRXC) rose 6 percent to $3.10 in pre-market trading after reporting a loan deal for $40 million in term loans with Hercules Capital.
    Stage Stores, Inc. (NYSE: SSI) rose 5.6 percent to $3.40 in pre-market trading following Q1 results.
    Koss Corporation (NASDAQ: KOSS) shares rose 5.2 percent to $2.42 in the pre-market trading session after falling 2.54 percent on Wednesday.

     

  • [By Money Morning Staff Reports]

    However, Seven Star’s gains are already on the books. After looking at last week’s top performing penny stocks, we’ll show you a penny stock on the verge of jumping over 70%…

    Penny Stock Current Share Price Last Week’s Gain
    Seven Stars Cloud Group Inc. (Nasdaq: SSC) $4.49 175.13%
    Alliance MMA Inc. (Nasdaq: AMMA) $0.37 121.05%
    India Globalization Capital Inc. (NYSE: IGC) $1.14 74.38%
    Obalon Therapeutics Inc. (Nasdaq: OBLN) $3.23 63.16%
    Cytori Therapeutics Inc. (Nasdaq: CYTX) $0.56 55.76%
    Atlanticus Holdings Corp. (Nasdaq: ATLC) $2.85 43.55%
    Research Frontiers Inc. (Nasdaq: REFR) $1.28 41.37%
    Koss Corp. (Nasdaq: KOSS) $4.08 41.28%
    GLG Life Tech Corp. (TSE: GLG) $0.88 33.90%
    Geron Corp. (Nasdaq: GERN) $4.76 32.40%

    While those gains are already in the book, you don’t have to miss out on the next penny stocks to soar.

Top 10 High Tech Stocks To Own Right Now: Unilever NV(UN)

Advisors’ Opinion:

  • [By Jeremy Bowman]

    Procter & Gamble (NYSE:PG) and Unilever (NYSE:UL) (NYSE:UN) have long been the two companies that have most defined the household goods space, dominating categories like detergent, soap, deodorant, and condiments, to name only a few.

  • [By Shanthi Rexaline]

    Unilever NV (ADR) ADR (NYSE: UN) procures sustainable oils such as soy, sunflower and rapeseed oil for a host of its consumer products such as Hellmann's mayonnaise. It remains to be seen how the U.S.-China standoff will hurt its margins.

  • [By Joseph Griffin]

    Stepan (NYSE: SCL) and Unilever (NYSE:UN) are both basic materials companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

  • [By Stephan Byrd]

    Guyasuta Investment Advisors Inc. raised its position in shares of Unilever NV (NYSE:UN) by 1.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 459,725 shares of the company’s stock after buying an additional 4,520 shares during the period. Unilever comprises about 2.9% of Guyasuta Investment Advisors Inc.’s holdings, making the stock its 9th largest holding. Guyasuta Investment Advisors Inc.’s holdings in Unilever were worth $25,616,000 at the end of the most recent reporting period.

  • [By Joseph Griffin]

    Unilever (NYSE:UN) has earned an average recommendation of “Hold” from the nine research firms that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have given a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company.

Top 10 High Tech Stocks To Own Right Now: Walker & Dunlop, Inc.(WD)

Advisors’ Opinion:

  • [By Dan Caplinger]

    For more than a decade, the real estate market has rebounded from the housing bust in the mid-2000s that led to the financial crisis. Since then, demand for both residential and commercial properties has been strong, and Walker & Dunlop (NYSE:WD) has capitalized by offering multiple methods of financing to real estate developers. Yet at long last, rising interest rates have started to raise concerns among real estate investors that the long bull market in the asset class could finally come to an end.

  • [By Ethan Ryder]

    Walker & Dunlop, Inc. (NYSE:WD) – Equities research analysts at Wedbush raised their Q1 2019 earnings estimates for shares of Walker & Dunlop in a report released on Monday, February 11th. Wedbush analyst H. Coffey now forecasts that the financial services provider will post earnings of $1.05 per share for the quarter, up from their previous forecast of $0.99. Wedbush has a “Outperform” rating and a $58.00 price objective on the stock. Wedbush also issued estimates for Walker & Dunlop’s Q2 2019 earnings at $1.26 EPS, Q3 2019 earnings at $1.53 EPS, Q4 2019 earnings at $1.56 EPS, FY2019 earnings at $5.40 EPS and FY2020 earnings at $5.95 EPS.

  • [By Keith Speights]

    Gilead Sciences (NASDAQ:GILD), Micron Technology (NASDAQ:MU), and Walker & Dunlop (NYSE:WD) actually have relatively low valuations. Here’s why these are three bargain stocks you can buy right now. 

  • [By Logan Wallace]

    Boston Partners increased its holdings in Walker & Dunlop, Inc. (NYSE:WD) by 3.1% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,495,943 shares of the financial services provider’s stock after buying an additional 45,657 shares during the period. Boston Partners owned about 4.82% of Walker & Dunlop worth $83,249,000 as of its most recent filing with the Securities & Exchange Commission.

Top 10 High Tech Stocks To Own Right Now: Imperial Oil Limited(IMO)

Advisors’ Opinion:

  • [By Logan Wallace]

    Imperial Oil Ltd (NYSEAMERICAN:IMO) (TSE:IMO) saw a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 11,491,321 shares, an increase of 1.1% from the May 31st total of 11,363,187 shares. Based on an average trading volume of 400,912 shares, the days-to-cover ratio is presently 28.7 days.

  • [By Shane Hupp]

    Swiss National Bank cut its position in shares of Imperial Oil (NYSEAMERICAN:IMO) (TSE:IMO) by 6.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,066,300 shares of the energy company’s stock after selling 76,100 shares during the period. Swiss National Bank owned approximately 0.13% of Imperial Oil worth $28,203,000 at the end of the most recent quarter.

  • [By Joseph Griffin]

    Citadel Advisors LLC purchased a new stake in shares of Imperial Oil Ltd (NYSEAMERICAN:IMO) (TSE:IMO) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 44,728 shares of the energy company’s stock, valued at approximately $1,487,000.

Top 10 High Tech Stocks To Own Right Now: 1-800 FLOWERS.COM Inc.(FLWS)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on 1-800-Flowers.Com (FLWS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    1-800-Flowers.Com (NASDAQ:FLWS)‘s stock had its “buy” rating restated by analysts at Benchmark in a research note issued on Wednesday, Marketbeat.com reports. They presently have a $16.00 price objective on the specialty retailer’s stock, up from their previous price objective of $14.00. Benchmark’s price objective would suggest a potential upside of 26.28% from the company’s previous close.

  • [By Motley Fool Transcribers]

    1-800-Flowers.com Inc (NASDAQ:FLWS)Q4 2018 Earnings Conference CallAug. 23, 2018, 11:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top 10 High Tech Stocks To Own Right Now: Prudential Public Limited Company(PUK)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Prudential Public Limited (NYSE:PUK) has earned a consensus recommendation of “Hold” from the six analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company.

  • [By Ethan Ryder]

    Prudential (NYSE: PUK) and Reinsurance Group of America (NYSE:RGA) are both finance companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

  • [By Ethan Ryder]

    ValuEngine lowered shares of Prudential (NYSE:PUK) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning.

    Several other analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of Prudential from a hold rating to a buy rating and set a $57.00 target price on the stock in a research note on Tuesday, March 27th. Berenberg Bank cut shares of Prudential from a hold rating to a sell rating in a research note on Thursday, March 29th. Finally, Citigroup cut shares of Prudential from a buy rating to a neutral rating in a research note on Wednesday, April 25th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. The stock currently has an average rating of Hold and an average price target of $57.00.

  • [By Stephan Byrd]

    Here are some of the news headlines that may have effected Accern’s rankings:

    Get Prudential alerts:

    Zacks Investment Research Lowers Prudential (PUK) to Hold (americanbankingnews.com) Financial wellness program popularity rises among employers, up 63 percentage points in two years (markets.financialcontent.com) FY2018 EPS Estimates for Prudential (PUK) Reduced by Jefferies Group (americanbankingnews.com) Jefferies Group Weighs in on Prudential’s FY2020 Earnings (PUK) (americanbankingnews.com) ValuEngine Downgrades Prudential (PUK) to Hold (americanbankingnews.com)

    Shares of PUK stock traded down $0.02 during trading on Tuesday, hitting $51.56. 141,455 shares of the stock traded hands, compared to its average volume of 198,097. The firm has a market cap of $66.49 billion, a PE ratio of 13.79, a PEG ratio of 1.34 and a beta of 1.55. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.03 and a current ratio of 0.03. Prudential has a 52-week low of $44.49 and a 52-week high of $55.36.

Top 10 High Tech Stocks To Own Right Now: ThyssenKrupp AG (TYEKF)

Advisors’ Opinion:

  • [By ]

    United Technologies’ Otis division manufactures and services elevators, escalators, and other people moving devices. The business is reasonably attractive since there is a fair degree of concentration. Four major companies, Kone Oyj (OTCPK:KNYJF) (OTCPK:KNYJY), ThyssenKrupp (OTCPK:TYEKF) (OTCPK:TKAMY), Schindler (OTCPK:SHLAF) (OTC:SHNDY), and Otis, account for over 50% market share. The main long-term drivers of the industry are urbanization. As you might guess, elevator demand is strongest in dense urban environments where almost every building is multi-story.

Top 10 High Tech Stocks To Own Right Now: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Shane Hupp]

    Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Ultragenyx launched its second drug, Crysvita, in the United States to treat X-linked hypophosphatemia (XLH) in April. We are optimistic on the drug’s uptake. The drug was also approved in the EU in February on a conditional basis. In May, the company announced positive phase II data from the drug in pediatric setting, but according to the FDA those were not sufficient to support an NDA. Thus, the company is in discussions with FDA and EMA, which would provide further clarity regarding whether an additional study would be required for the approval. The company also remains focused on its two-gene therapy programs — DTX301 for ornithine transcarbamylase deficiency and DTX401 for glycogen storage disease type Ia. However, developmental or regulatory setbacks could result in higher operating expenses and the need for additional capital. Loss estimates have narrowed ahead of  Q3 earnings release.”

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Chris Lange]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is expected to report Phase 2 data from all its tumor-induced osteomalacia patients. Shares of Ultragenyx closed Friday at $76.87, in a 52-week range of $41.67 to $86.10 and with a consensus analyst target of $68.74.

  • [By Shane Hupp]

    These are some of the media headlines that may have effected Accern’s scoring:

    Get Ultragenyx Pharmaceutical alerts:

    Burosumab Improves Outcomes in Children with XLH in Phase 2 Trial (raredr.com) RARE Stock Is on the Verge of Breaking Out Toward Higher Prices (profitconfidential.com) Burosumab may benefit children with X-linked hypophosphatemia (medicalxpress.com) A Look Inside the Quant Data For Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) (parkcitycaller.com) Ultragenyx Pharmaceutical Inc. (RARE)- Stock in the Trader’s Radar (nasdaqfortune.com)

    A number of research firms have recently weighed in on RARE. ValuEngine raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday. BidaskClub raised Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 19th. Barclays raised Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $62.00 to $74.00 in a report on Friday, May 11th. Goldman Sachs Group began coverage on Ultragenyx Pharmaceutical in a report on Thursday, May 10th. They set a “neutral” rating and a $63.00 target price for the company. Finally, Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $70.06.

  • [By Motley Fool Transcribers]

    Ultragenyx Pharmaceutical Inc  (NASDAQ:RARE)Q4 2018 Earnings Conference CallFeb. 19, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Joseph Griffin]

    BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Monday.

    A number of other brokerages have also recently weighed in on RARE. JPMorgan Chase restated an overweight rating and issued a $66.00 price objective (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a research note on Monday, January 22nd. Stifel Nicolaus restated a buy rating and issued a $74.00 price objective (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 4th. Finally, Wedbush reiterated a positive rating and set a $71.00 target price (up from $64.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of Buy and an average price target of $69.76.

Top 10 High Tech Stocks To Own Right Now: GWG Holdings, Inc(GWGH)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on GWG (GWGH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Here are some of the news articles that may have effected Accern Sentiment’s analysis:

    Get GWG alerts:

    Critical Review: Citizens (CIA) vs. GWG (GWGH) (americanbankingnews.com) (Watch) Zibanejad scores in Sweden’s win over Russia (sny.tv) GWG Holdings’ (GWGH) CEO Jon Sabes on Q1 2018 Results – Earnings Call Transcript (msn.com) Edited Transcript of GWGH earnings conference call or presentation 14-May-18 8:30pm GMT (finance.yahoo.com) DWWA judge profile: Davide Buongiorno (decanter.com)

    A number of equities research analysts recently commented on the company. Zacks Investment Research raised GWG from a “hold” rating to a “buy” rating and set a $9.25 price target for the company in a research report on Wednesday, April 11th. ValuEngine lowered GWG from a “hold” rating to a “sell” rating in a research report on Monday, May 14th. Finally, Maxim Group reaffirmed a “buy” rating and set a $14.00 target price on shares of GWG in a research report on Tuesday, January 23rd.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on GWG (GWGH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on GWG (GWGH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Undervalued Stocks To Watch For 2019

The reason why the growth stocks do so much better is that they seem to show gains in value in the hundreds of percent each decade. In contrast, it is an unusual bargain that is as much as 50 percent undervalued. The cumulative effect of this simple arithmetic should be obvious. – Philip Fisher (the Father of Growth Investing)

On Jan 05, 2018, the share price of Crispr Therapeutics (NASDAQ:CRSP), a bioscience focusing on gene-editing and CAR-T to treat serious conditions such as cancers and genetic diseases, continued its rally. The stock added another $2.90 (over 12% profits) to value at $26.81 for the said trading session. Since we recommended the company on Nov. 27, 2017 (just over a month) to subscribers of Integrated BioSci Investing, the stock added another $7.26 (or 37% in capital appreciation). This robust run-up is interesting because, on Jan. 04, 2018, the company announced that the 5M additional common shares issued on Jan 03 will be priced at $22.75.

Top 10 Undervalued Stocks To Watch For 2019: Internap Network Services Corporation(INAP)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Internap (NASDAQ:INAP) issued its quarterly earnings data on Thursday. The information technology services provider reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.13), MarketWatch Earnings reports. The business had revenue of $74.20 million for the quarter, compared to analyst estimates of $73.99 million. Internap had a negative return on equity of 271.76% and a negative net margin of 16.15%. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.02) earnings per share.

  • [By Shane Hupp]

    GDS (NASDAQ: INAP) and Internap (NASDAQ:INAP) are both business services companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Internap (INAP)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Shares of Internap Corp (NASDAQ:INAP) saw unusually-strong trading volume on Tuesday . Approximately 1,086,029 shares traded hands during mid-day trading, an increase of 306% from the previous session’s volume of 267,673 shares.The stock last traded at $5.85 and had previously closed at $5.32.

  • [By Stephan Byrd]

    Internap Corp (NASDAQ:INAP) has received an average rating of “Buy” from the six analysts that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating, one has issued a buy rating and two have given a strong buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $28.00.

Top 10 Undervalued Stocks To Watch For 2019: KLX Inc.(KLXI)

Advisors’ Opinion:

  • [By Logan Wallace]

    OppenheimerFunds Inc. decreased its position in KLX Inc (NASDAQ:KLXI) by 16.2% in the 1st quarter, Holdings Channel reports. The firm owned 7,067 shares of the aerospace company’s stock after selling 1,367 shares during the period. OppenheimerFunds Inc.’s holdings in KLX were worth $502,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Rich Smith]

    KLX Inc. (NASDAQ:KLXI) stock closed 15.2% lower on Monday. That sounds like bad news, but really isn’t. Here’s why.

    So what

    KLX is a strange beast, as it comprises two main business units. The Aerospace Solutions Group distributes small airplane components such as bolts, clips, hinges, and screws. With $1.4 billion in annual sales, this is KLX’s largest business unit — and it’s selling out to Boeing in a $4.25 billion deal initially expected to close sometime in this current third quarter of 2018  — later postponed to Q4.

  • [By Shane Hupp]

    KLX (NASDAQ:KLXI) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Friday.

  • [By Max Byerly]

    BidaskClub downgraded shares of KLX (NASDAQ:KLXI) from a buy rating to a hold rating in a report released on Tuesday morning.

    KLXI has been the subject of several other reports. SunTrust Banks cut shares of KLX from a buy rating to a hold rating and set a $53.00 target price for the company. in a report on Wednesday, May 2nd. Zacks Investment Research cut shares of KLX from a buy rating to a hold rating in a report on Saturday, February 17th. TheStreet cut shares of KLX from a b rating to a c+ rating in a report on Tuesday, March 6th. Finally, Jefferies Group upgraded shares of KLX from a hold rating to a buy rating in a report on Wednesday, March 7th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of Hold and a consensus target price of $66.50.

Top 10 Undervalued Stocks To Watch For 2019: Discover Financial Services(DFS)

Advisors’ Opinion:

  • [By Matthew Cochrane]

    Over the past several quarters, Discover Financial Services (NYSE:DFS) has struggled to strike the proper balance between growing its loan portfolios and keeping its credit default risks in check. At least, that’s what Wall Street would have you believe. Discover’s management, however, maintains credit risk concerns are overblown. Meanwhile, the company continues to grow its loan portfolios at steady clips.

  • [By Joseph Griffin]

    DFS Furniture (LON:DFS)‘s stock had its “buy” rating reissued by analysts at Peel Hunt in a research note issued to investors on Thursday.

  • [By ]

    Selected examples: (BXP) , (DFS) , (HST) , (MA) , (TXN) , (USB) .

    Inflation Is a Key Risk

    Execs were most worried about inflation, as they should be.

Top 10 Undervalued Stocks To Watch For 2019: Gulfport Energy Corporation(GPOR)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Liberty Mutual Group Asset Management Inc. lowered its stake in Gulfport Energy Co. (NASDAQ:GPOR) by 22.3% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,452 shares of the oil and gas producer’s stock after selling 9,320 shares during the quarter. Liberty Mutual Group Asset Management Inc.’s holdings in Gulfport Energy were worth $313,000 at the end of the most recent reporting period.

  • [By Joseph Griffin]

    Gulfport Energy (NASDAQ: GPOR) and Callitas Health (OTCMKTS:MPHMF) are both small-cap oils/energy companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

  • [By Shane Hupp]

    Gulfport Energy Co. (NASDAQ:GPOR) saw some unusual options trading activity on Monday. Stock investors bought 43,045 call options on the stock. This is an increase of approximately 1,866% compared to the typical volume of 2,190 call options.

  • [By Max Byerly]

    Liberum Capital reissued their hold rating on shares of Great Portland Estates (LON:GPOR) in a research note published on Wednesday morning.

    GPOR has been the subject of a number of other reports. Barclays increased their price objective on shares of Great Portland Estates from GBX 560 ($7.51) to GBX 580 ($7.78) and gave the company an underweight rating in a report on Thursday, February 22nd. Deutsche Bank reaffirmed a hold rating on shares of Great Portland Estates in a report on Friday, March 2nd. Goldman Sachs Group cut their price objective on shares of Great Portland Estates from GBX 675 ($9.06) to GBX 665 ($8.92) and set a neutral rating for the company in a report on Wednesday, March 14th. Morgan Stanley increased their price objective on shares of Great Portland Estates from GBX 620 ($8.32) to GBX 660 ($8.86) and gave the company an underweight rating in a report on Tuesday, March 13th. Finally, Citigroup raised their target price on shares of Great Portland Estates from GBX 700 ($9.39) to GBX 735 ($9.86) and gave the company a neutral rating in a report on Wednesday, May 2nd. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company. Great Portland Estates has a consensus rating of Hold and a consensus target price of GBX 662.15 ($8.88).

  • [By Logan Wallace]

    Gulfport Energy Co. (NASDAQ:GPOR) – Stock analysts at Seaport Global Securities upped their Q3 2018 earnings per share estimates for Gulfport Energy in a research note issued on Wednesday, May 23rd. Seaport Global Securities analyst M. Kelly now expects that the oil and gas producer will post earnings of $0.33 per share for the quarter, up from their prior estimate of $0.22. Seaport Global Securities also issued estimates for Gulfport Energy’s Q4 2018 earnings at $0.43 EPS, FY2018 earnings at $1.63 EPS, Q2 2019 earnings at $0.28 EPS, Q3 2019 earnings at $0.28 EPS, Q4 2019 earnings at $0.35 EPS and FY2019 earnings at $1.22 EPS.

  • [By Paul Ausick]

    Gulfport Energy Corp. (NASDAQ: GPOR) traded down about 10% Tuesday and posted a new 52-week low of $10.90 after closing Monday at $12.12. The stock’s 52-week high is $9.75. Volume was over 12 million, nearly four times the daily average of about 3.4million shares. The company had no specific news announced its capital budget and a stock repurchase program after markets closed Monday.

Top 10 Undervalued Stocks To Watch For 2019: ITUS Corporation(ITUS)

Advisors’ Opinion:

  • [By Joseph Griffin]

    ITUS Corp (NASDAQ:ITUS) CEO Amit Kumar bought 4,480 shares of ITUS stock in a transaction dated Wednesday, September 12th. The shares were purchased at an average cost of $3.99 per share, for a total transaction of $17,875.20. Following the completion of the transaction, the chief executive officer now owns 128,888 shares of the company’s stock, valued at approximately $514,263.12. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Top 10 Undervalued Stocks To Watch For 2019: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Shane Hupp]

    These are some of the media headlines that may have effected Accern’s scoring:

    Get Ultragenyx Pharmaceutical alerts:

    Burosumab Improves Outcomes in Children with XLH in Phase 2 Trial (raredr.com) RARE Stock Is on the Verge of Breaking Out Toward Higher Prices (profitconfidential.com) Burosumab may benefit children with X-linked hypophosphatemia (medicalxpress.com) A Look Inside the Quant Data For Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) (parkcitycaller.com) Ultragenyx Pharmaceutical Inc. (RARE)- Stock in the Trader’s Radar (nasdaqfortune.com)

    A number of research firms have recently weighed in on RARE. ValuEngine raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday. BidaskClub raised Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 19th. Barclays raised Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $62.00 to $74.00 in a report on Friday, May 11th. Goldman Sachs Group began coverage on Ultragenyx Pharmaceutical in a report on Thursday, May 10th. They set a “neutral” rating and a $63.00 target price for the company. Finally, Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $70.06.

  • [By Shane Hupp]

    Ultragenyx Pharmaceutical (NASDAQ:RARE) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Ultragenyx launched its second drug, Crysvita, in the United States to treat X-linked hypophosphatemia (XLH) in April. We are optimistic on the drug’s uptake. The drug was also approved in the EU in February on a conditional basis. In May, the company announced positive phase II data from the drug in pediatric setting, but according to the FDA those were not sufficient to support an NDA. Thus, the company is in discussions with FDA and EMA, which would provide further clarity regarding whether an additional study would be required for the approval. The company also remains focused on its two-gene therapy programs — DTX301 for ornithine transcarbamylase deficiency and DTX401 for glycogen storage disease type Ia. However, developmental or regulatory setbacks could result in higher operating expenses and the need for additional capital. Loss estimates have narrowed ahead of  Q3 earnings release.”

  • [By Joseph Griffin]

    BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Monday.

    A number of other brokerages have also recently weighed in on RARE. JPMorgan Chase restated an overweight rating and issued a $66.00 price objective (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a research note on Monday, January 22nd. Stifel Nicolaus restated a buy rating and issued a $74.00 price objective (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 4th. Finally, Wedbush reiterated a positive rating and set a $71.00 target price (up from $64.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of Buy and an average price target of $69.76.

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Chris Lange]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is expected to report Phase 2 data from all its tumor-induced osteomalacia patients. Shares of Ultragenyx closed Friday at $76.87, in a 52-week range of $41.67 to $86.10 and with a consensus analyst target of $68.74.

Top 10 Undervalued Stocks To Watch For 2019: Cytosorbents Corporation(CTSO)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Cytosorbents Corp (NASDAQ:CTSO) COO Vincent Capponi sold 9,565 shares of the company’s stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $13.00, for a total value of $124,345.00. Following the completion of the transaction, the chief operating officer now owns 342,333 shares in the company, valued at approximately $4,450,329. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

  • [By Motley Fool Transcribers]

    Cytosorbents Corp  (NASDAQ:CTSO)Q4 2018 Earnings Conference CallMarch 07, 2019, 4:45 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Shane Hupp]

    Cytosorbents (NASDAQ:CTSO) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a report issued on Thursday.

Top 10 Undervalued Stocks To Watch For 2019: Ebix, Inc.(EBIX)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Wall Street seemed to phone it in on Monday, with low volume and fairly modest moves for most major benchmarks reflecting the fact that many federal and state government offices were closed for a holiday. Interest rates stabilized after a substantial jump last week, but market participants are still working through the potential consequences of the rate rise that resulted in 10-year Treasury yields hitting their highest levels since the early 2010s. Moreover, some negative news regarding individual companies weighed on sentiment. Square (NYSE:SQ), Ebix (NASDAQ:EBIX), and iRobot (NASDAQ:IRBT) were among the worst performers on the day. Here’s why they did so poorly.

  • [By Motley Fool Transcribers]

    Ebix Inc  (NASDAQ:EBIX)Q4 2018 Earnings Conference CallMarch 01, 2019, 11:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Max Byerly]

    Shares of Ebix Inc (NASDAQ:EBIX) were down 5.8% during mid-day trading on Tuesday . The stock traded as low as $57.66 and last traded at $61.47. Approximately 18,499 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 189,931 shares. The stock had previously closed at $58.10.

  • [By Shane Hupp]

    Ebix (NASDAQ: EBIX) and Godaddy (NYSE:GDDY) are both computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

  • [By Shane Hupp]

    Shares of Ebix Inc (NASDAQ:EBIX) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $100.00.

  • [By Ethan Ryder]

    Ebix (NASDAQ:EBIX) issued its earnings results on Wednesday. The technology company reported $0.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.01), MarketWatch Earnings reports. The business had revenue of $108.23 million for the quarter, compared to analysts’ expectations of $106.81 million. Ebix had a return on equity of 20.67% and a net margin of 27.65%. Ebix’s revenue for the quarter was up 36.8% on a year-over-year basis.

Top 10 Undervalued Stocks To Watch For 2019: Hanesbrands Inc.(HBI)

Advisors’ Opinion:

  • [By Dan Caplinger]

    Wall Street started the week on a muted note on Monday, as major benchmarks generally closed slightly down. Much of the attention among investors was on the bond market, where 10-year Treasury yields rose as high as 2.99%, signaling to some the possibility of much higher financing costs that could punish companies that overextended their balance sheets with debt when rates were much lower. Yet some individual companies had good news that sent their shares higher. McDermott International (NYSE:MDR), Box (NYSE:BOX), and Hanesbrands (NYSE:HBI) were among the best performers on the day. Here’s why they did so well.

  • [By Stephan Byrd]

    Morgan Stanley increased its position in shares of Hanesbrands Inc. (NYSE:HBI) by 13.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,095,675 shares of the textile maker’s stock after acquiring an additional 362,960 shares during the period. Morgan Stanley owned about 0.86% of Hanesbrands worth $68,166,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Hanesbrands (HBI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Hanesbrands (HBI)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Keith Noonan]

    The strategy might not produce huge gains overnight, but patient investors can see strong returns with a value-focused, buy-to-hold approach to dividend stocks. Within that mold, investors seeking solid, income-generating stocks should consider establishing or adding to positions in Hanesbrands (NYSE:HBI) and AT&T (NYSE:T) — two companies that are consistently profitable, trade at non-prohibitive valuations, and pay sizable dividends. 

  • [By Keith Noonan]

    For this dive into promising income-generating stocks, I’ll be looking at three companies that have recently been making headlines for their strong performances. Two are technology giants that are benefiting from the growth of recurring revenue streams — Cisco Systems (NASDAQ:CSCO) and Microsoft (NASDAQ:MSFT) — and the other is an apparel stalwart on the rebound as one of its key lines is heating up — Hanesbrands (NYSE:HBI).

Top 10 Undervalued Stocks To Watch For 2019: The First of Long Island Corporation(FLIC)

Advisors’ Opinion:

  • [By Ethan Ryder]

    1ST RES BK EXTO/SH (OTCMKTS:FRSB) and First of Long Island (NASDAQ:FLIC) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

  • [By Stephan Byrd]

    COPYRIGHT VIOLATION WARNING: “First of Long Island Corp (FLIC) Position Trimmed by ClariVest Asset Management LLC” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at www.tickerreport.com/banking-finance/4167612/first-of-long-island-corp-flic-position-trimmed-by-clarivest-asset-management-llc.html.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on First of Long Island (FLIC)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    First of Long Island Corp (NASDAQ:FLIC) hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $21.30 and last traded at $21.60, with a volume of 237 shares. The stock had previously closed at $21.50.

  • [By Stephan Byrd]

    First of Long Island (NASDAQ:FLIC) and 1ST RES BK EXTO/SH (OTCMKTS:FRSB) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

Top Warren Buffett Stocks To Invest In Right Now

Tell us how you really feel, Mr. Buffett.

The price of bitcoin took a dive after Warren Buffett renewed his criticism of the cryptocurrency even comparing it to rat poison.

Bitcoin had been closing in on $10,000, but it fell nearly 6% Sunday and was down another 2% Monday to just over $9,300.

Buffett, the CEO of Berkshire Hathaway (BRKB), has been a bitcoin bear for years. He has often compared the cryptocurrency to gold, saying that both assets are strictly speculative and don’t produce earnings and dividends like stocks do.

Before the Berkshire annual meeting on Saturday, Buffett told CNBC that bitcoin was “probably rat poison squared.”

During the meeting itself, Buffett joked that “if you had bought gold at the time of Christ and you figure the compound rate on it, it’s a couple tenths of a percent.” What Buffett was saying about bitcoin was that you can buy it, but it will never produce anything of value.

He also responded to a question from the audience about bitcoin by saying that it and other crytpocurrencies “will come to bad endings.”

Top Warren Buffett Stocks To Invest In Right Now: Ultralife Corporation(ULBI)

Advisors’ Opinion:

  • [By Shane Hupp]

    Polar Power (NASDAQ: POLA) and Ultralife (NASDAQ:ULBI) are both small-cap utilities companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Top Warren Buffett Stocks To Invest In Right Now: United Fire Group, Inc(UFCS)

Advisors’ Opinion:

  • [By Shane Hupp]

    United Fire & Casualty (NASDAQ:UFCS) shares hit a new 52-week high and low during mid-day trading on Friday . The stock traded as low as $53.47 and last traded at $53.26, with a volume of 1018 shares trading hands. The stock had previously closed at $51.84.

  • [By Lee Jackson]

    United Fire Group Inc. (NASDAQ: UFCS) was downgraded to hold from buy at Sandler ONeill. The 52-week trading range for the shares has been $38.95 to $58.46. The stock closed Monday at $56, so this could be another valuation call.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on United Fire Group (UFCS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Earnest Partners LLC grew its stake in shares of United Fire Group, Inc. (NASDAQ:UFCS) by 2.6% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,449,353 shares of the insurance provider’s stock after acquiring an additional 36,932 shares during the quarter. Earnest Partners LLC owned about 0.06% of United Fire Group worth $69,366,000 as of its most recent SEC filing.

  • [By Stephan Byrd]

    United Fire Group (NASDAQ:UFCS) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Friday.

  • [By Shane Hupp]

    Shares of United Fire & Casualty (NASDAQ:UFCS) hit a new 52-week high and low during trading on Thursday following a dividend announcement from the company. The company traded as low as $52.90 and last traded at $52.61, with a volume of 2181 shares trading hands. The stock had previously closed at $51.78.

Top Warren Buffett Stocks To Invest In Right Now: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Chris Lange]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is expected to report Phase 2 data from all its tumor-induced osteomalacia patients. Shares of Ultragenyx closed Friday at $76.87, in a 52-week range of $41.67 to $86.10 and with a consensus analyst target of $68.74.

  • [By Shane Hupp]

    These are some of the media headlines that may have effected Accern’s scoring:

    Get Ultragenyx Pharmaceutical alerts:

    Burosumab Improves Outcomes in Children with XLH in Phase 2 Trial (raredr.com) RARE Stock Is on the Verge of Breaking Out Toward Higher Prices (profitconfidential.com) Burosumab may benefit children with X-linked hypophosphatemia (medicalxpress.com) A Look Inside the Quant Data For Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) (parkcitycaller.com) Ultragenyx Pharmaceutical Inc. (RARE)- Stock in the Trader’s Radar (nasdaqfortune.com)

    A number of research firms have recently weighed in on RARE. ValuEngine raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday. BidaskClub raised Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 19th. Barclays raised Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $62.00 to $74.00 in a report on Friday, May 11th. Goldman Sachs Group began coverage on Ultragenyx Pharmaceutical in a report on Thursday, May 10th. They set a “neutral” rating and a $63.00 target price for the company. Finally, Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $70.06.

  • [By Todd Campbell]

    A Genentech alumnus, Conner was previously vice president of clinical science at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biotech that has successfully developed therapies for rare and ultrarare diseases. Prior to that, he was senior medical director at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), another biotech company that’s successfully developed drugs for rare diseases.

  • [By Joseph Griffin]

    BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Monday.

    A number of other brokerages have also recently weighed in on RARE. JPMorgan Chase restated an overweight rating and issued a $66.00 price objective (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a research note on Monday, January 22nd. Stifel Nicolaus restated a buy rating and issued a $74.00 price objective (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 4th. Finally, Wedbush reiterated a positive rating and set a $71.00 target price (up from $64.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of Buy and an average price target of $69.76.

Top Warren Buffett Stocks To Invest In Right Now: Lexington Realty Trust(LXP)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Lexington Realty Trust (NYSE:LXP) is scheduled to be releasing its earnings data before the market opens on Tuesday, May 8th. Analysts expect Lexington Realty Trust to post earnings of $0.06 per share for the quarter. Lexington Realty Trust has set its FY18 guidance at $0.95-0.98 EPS.

  • [By Max Byerly]

    ValuEngine upgraded shares of Lexington Realty Trust (NYSE:LXP) from a strong sell rating to a sell rating in a research note released on Friday.

    Several other brokerages have also weighed in on LXP. Stifel Nicolaus lowered Lexington Realty Trust from a hold rating to a sell rating and cut their price target for the company from $8.50 to $7.00 in a research note on Tuesday, May 8th. Zacks Investment Research upgraded Lexington Realty Trust from a sell rating to a hold rating in a research note on Saturday, May 12th. Barclays cut their price target on Lexington Realty Trust from $10.00 to $9.00 and set an underweight rating for the company in a research note on Tuesday, March 20th. Wells Fargo & Co cut their price target on Lexington Realty Trust from $11.00 to $9.00 and set a market perform rating for the company in a research note on Monday, March 19th. Finally, JPMorgan Chase & Co. lowered their price objective on Lexington Realty Trust from $10.00 to $9.00 and set a neutral rating on the stock in a report on Tuesday, April 10th. Four equities research analysts have rated the stock with a sell rating and eight have assigned a hold rating to the stock. Lexington Realty Trust has a consensus rating of Hold and an average price target of $9.68.

  • [By Ethan Ryder]

    Lexington Realty Trust (NYSE:LXP) was downgraded by equities researchers at Stifel Nicolaus from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday, MarketBeat reports. They currently have a $7.00 target price on the real estate investment trust’s stock, down from their previous target price of $8.50. Stifel Nicolaus’ price target suggests a potential downside of 15.66% from the stock’s current price.

what is equity market

As expected, the path of the S&P 500 in the first week of October 2016 came in below our standard model’s projections, as stock prices continued their mostly sideways trajectory of the last three months, although with a slightly downward course.

Click to enlarge

Coming into the week, investors appeared to be focusing their attention on the first quarter of 2017 in setting stock prices, but that downward path, combined with the news of the week suggests that may have changed, where they are perhaps now focusing more on 2016-Q4.

what is equity market: Addus HomeCare Corporation(ADUS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Marathon Patent Group Inc (NASDAQ: MARA) shares rose 47.1 percent to $3.22 in pre-market trading after jumping 54.23 percent on Wednesday.
    Digital Power Corporation (NYSE: DPW) rose 27.6 percent to $0.800 in pre-market trading after gaining 9.79 percent on Wednesday.
    Social Reality Inc (NASDAQ: SRAX) shares rose 23.1 percent to $7.16 in the pre-market trading session after surging 37.59 percent on Wednesday.
    China Auto Logistics Inc (NASDAQ: CALA) rose 16.9 percent to $4.15 in pre-market trading after gaining 4.11 percent on Wednesday.
    Riot Blockchain Inc (NASDAQ: RIOT) rose 15.1 percent to $18.40 in pre-market trading after climbing 42.01 percent on Wednesday.
    Seven Stars Cloud Group Inc (NASDAQ: SSC) rose 14.5 percent to $2.85 in the pre-market trading session after gaining 0.40 percent on Wednesday.
    Affimed NV (NASDAQ: AFMD) shares rose 14.3 percent to $2.40 in pre-market trading after gaining 4.88 percent on Wednesday.
    Corecivic Inc (NYSE: CXW) rose 10.2 percent to $25.56 in pre-market trading after climbing 0.65 percent on Wednesday.
    LM Funding America, Inc. (NASDAQ: LMFA) rose 9.6 percent to $3.30 in pre-market trading after surging 34.98 percent on Wednesday.
    U.S. Global Investors, Inc. (NASDAQ: GROW) rose 7.2 percent to $3.30 in pre-market trading after dropping 8.06 percent on Wednesday.
    Xunlei Ltd (NASDAQ: XNET) rose 6.8 percent to $25.61 in pre-market trading after climbing 11.74 percent on Wednesday.
    Net 1 UEPS Technologies Inc (NASDAQ: UEPS) shares rose 5.9 percent to $13.00 in pre-market trading after gaining 21.34 percent on Wednesday.
    Addus Homecare Corporation (NASDAQ: ADUS) rose 5.5 percent to $35.60 in pre-market trading after gaining 3.69 percent on Wednesday.
    TOP SHIPS Inc (NASDAQ: TOPS) rose 5.2 percent to $0.528 in pre-market trading after falling 10.36 percent on Wednesday.
    Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) rose 4.7 percent to $14.11 in pre-market trading. Teva Pharma

what is equity market: Xerox Corporation(XRX)

Advisors’ Opinion:

  • [By Paul Ausick]

    Xerox Corp. (NYSE: XRX) dropped about 23% on Tuesday to post a new 52-week low of $6.46 after closing at $8.73 on Friday. The dip was the result of the company’s completed separation into two firms this morning. After the early drop shares had gained around 17% by late afternoon, probably on the strength of a cash payment of $1.8 billion.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Monday was Xerox Corp. (NYSE: XRX) which rose 3.8% to $30.56. The stocks 52-week range is $22.90 to $30.76. Volume was 3.8 million compared to its average volume of 2.3 million.

what is equity market: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Johanna Bennett]

    Nothing guts a drug stock like bad clinical trial data. Shares of Ultragenyx Pharmaceutical (RARE) fell as much as 10% after a seizure medication failed in a phase II study.

    Trading at a recent $72.22, the shares were down 7.7% after earlier falling as much as 10% to $70.51

    The seizure drug UX007 was tested as a treatment for glucose transporter type-1 deficiency syndromeor Glut1 DSamong a small group of patients. Data released Wednesday showed that it only cut the rate of seizures in the drug arm by 13.4% compared to the placebo arm, falling short of statistical significance.

    Investigators, though, teased out a clinically — though not statistically — significant benefit for patients experiencing what are called absence seizures. Ultragenyx now intends to focus on that in a Phase III pivotal trial.

    Leerik analyst Joseph Schwartz called the selloff a buying opportunity.

    We had been cautious on this asset (and its two programs – G1DS and long-chain fatty acid oxidation disorder/LC-FAOD; LINK) – but believe the selling pressure after mkt. presents a buying opportunity ahead of a more de-risked X-linked hypophosphatemia (XLH) Ph.3 data in 1H17.

    Cowen analyst Eric Schmidt remained convinced of RAREs long-term prospects thanks to a diversified orphan disease pipeline. And analysts at Credit Suisse see more catalysts ahead in 2017.

    We are buyers on a pullback and we like RAREs setup for the remainder of 2017…Remaining 2017 catalysts keep us buyers on a pullback: We see Q2:17 KRN23 ph3 adult XLH data, H1:17 rhGUS FDA/EMA submission, potential KRN23 CHMP decision in mid-17 (based on late-2016 EMA submission/validation), H2:17 Ace-ER ph3 GNEM data, and potential KRN23 FDA submission in late-17/early-18 as upcoming catalysts worth owning for.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Jon C. Ogg]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was indicated down 7% at $72.85 on Thursday due to results from a seizure medication study. It was downgraded to Neutral from Overweight at Piper Jaffray, and Wedbushlowered its target for the stock.

what is equity market: Baidu Inc.(BIDU)

Advisors’ Opinion:

  • [By Stark Merrifield]

    To capitalize on the U.S.’ strong trade relationship with China, Fitz-Gerald suggests looking at companies like Alibaba Group Holding Ltd. (NYSE: BABA), “which dominates Chinese e-commerce the way Amazon.com Inc. (Nasdaq: AMZN) does in the United States,” or Baidu Inc. (Nasdaq: BIDU), which “mirrors Alphabet Inc. (Nasdaq: GOOGL).”

  • [By Joe Tenebruso]

    Netflix also just recently made inroads into the biggest international market of them all: China. It agreed to a licensing deal with iQiyi, Baidu’s (NASDAQ:BIDU) video streaming service. iQiyi is the most popular video streaming platform in China, with 500 million monthly viewers for its free service and 20 million paid subscribers. And while the terms of the deal were undisclosed, Netflix no doubt stands to benefit from the brand exposure that gaining access to iQiyi’s massive user base will provide.

  • [By WWW.THESTREET.COM]

    But Coursera co-founder Andrew Ng, who previously founded Google’s AI-powered Brain project and served as chief scientist of Baidu (BIDU) , is much more optimistic. Speaking at TechCrunch Disrupt on Wednesday, Ng detailed how AI is pegged to change the world for the better. It also won’t just be limited to Silicon Valley.

Top Performing Stocks To Watch Right Now

Source: ThinkstockDecember 19, 2017: The S&P 500 closed down 0.3% at 2,681.48. The DJIA closed down 0.15% at 24,754.26. Separately, the Nasdaq was down 0.4% at 6,963.85.

Tuesday started out as a great day for the markets, but quickly turned for the worse right out of the gate. While Monday showed a lot of promise for the major exchanges, Tuesday was a small step back. Crude oil was up for the session countering Mondays loss. The S&P 500 sectors were mostly negative on the day with a few small exceptions. The best performing sectors were energy and consumer staples up 0.1%, and 0.1%, respectively. The worst performing sectors were real estate, utilities, and technology down 1.9%, 1.8% and 0.6%, respectively.

Crude oil was up 0.6% at $57.49.

Top Performing Stocks To Watch Right Now: Moneygram International, Inc.(MGI)

Advisors’ Opinion:

  • [By Lisa Levin]

    Moneygram International Inc (NASDAQ: MGI) shares were also up, gaining 21 percent to $5.74 after the company reported upbeat Q4 earnings.

    Equities Trading DOWN

  • [By Jim Robertson]

    On Friday, our Under the Radar Moversnewsletter suggested shorting small capmoney transfer services stock Moneygram International (NASDAQ: MGI):

  • [By Ben Levisohn]

    Western Union (WU) soared to the top of the S&P 500 today after MoneyGram International (MGI) received a bid from Euronet Worldwide (EEFT).

    Agence France-Presse/Getty Images

    Shares of Western Union gained 3.5% to $20.27 today, while the S&P 500 fell 0.3% to 2,365.45.MoneyGram International surged 25% to $15.77, while Euronet Worldwide advanced 0.3% to $83.22.

Top Performing Stocks To Watch Right Now: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Johanna Bennett]

    Nothing guts a drug stock like bad clinical trial data. Shares of Ultragenyx Pharmaceutical (RARE) fell as much as 10% after a seizure medication failed in a phase II study.

    Trading at a recent $72.22, the shares were down 7.7% after earlier falling as much as 10% to $70.51

    The seizure drug UX007 was tested as a treatment for glucose transporter type-1 deficiency syndromeor Glut1 DSamong a small group of patients. Data released Wednesday showed that it only cut the rate of seizures in the drug arm by 13.4% compared to the placebo arm, falling short of statistical significance.

    Investigators, though, teased out a clinically — though not statistically — significant benefit for patients experiencing what are called absence seizures. Ultragenyx now intends to focus on that in a Phase III pivotal trial.

    Leerik analyst Joseph Schwartz called the selloff a buying opportunity.

    We had been cautious on this asset (and its two programs – G1DS and long-chain fatty acid oxidation disorder/LC-FAOD; LINK) – but believe the selling pressure after mkt. presents a buying opportunity ahead of a more de-risked X-linked hypophosphatemia (XLH) Ph.3 data in 1H17.

    Cowen analyst Eric Schmidt remained convinced of RAREs long-term prospects thanks to a diversified orphan disease pipeline. And analysts at Credit Suisse see more catalysts ahead in 2017.

    We are buyers on a pullback and we like RAREs setup for the remainder of 2017…Remaining 2017 catalysts keep us buyers on a pullback: We see Q2:17 KRN23 ph3 adult XLH data, H1:17 rhGUS FDA/EMA submission, potential KRN23 CHMP decision in mid-17 (based on late-2016 EMA submission/validation), H2:17 Ace-ER ph3 GNEM data, and potential KRN23 FDA submission in late-17/early-18 as upcoming catalysts worth owning for.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston
  • [By Jon C. Ogg]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was indicated down 7% at $72.85 on Thursday due to results from a seizure medication study. It was downgraded to Neutral from Overweight at Piper Jaffray, and Wedbushlowered its target for the stock.

Top Performing Stocks To Watch Right Now: Nuveen Municipal Value Fund Inc.(NUV)

Advisors’ Opinion:

  • [By Donald van Deventer]

    The latest implied forward rate forecast from Kamakura Corporation shows projected 10-year U.S. Treasury yields differing -0.07% to 0.03% from last week while fixed rate mortgage yields varied by -0.01% to 0.08%. Mortgage yields, determined by the Monday through Wednesday weekly survey of the Federal Home Loan Mortgage Corporation, lag Treasury movements simply because of the 3-day yield calculation used in the Primary Mortgage Market Survey. The 10-year U.S. Treasury yield is projected to rise from 2.92% at Thursday’s close (down 0.06% from last week) to 3.374% (down 0.06% from last week) in one year. The 10-year U.S. Treasury yield in ten years is forecast to reach 4.639%, 1 basis point lower than last week. The 15-year fixed rate mortgage rate is forecast to rise from the effective yield of 3.69% on Thursday (down 0.001% from last week) to 4.222% (down 0.006% from last week) in one year and 6.29% in 10 years, up 0.038% from last week. We explain the background for these calculations in the rest of this note, along with some mortgage servicing rights metrics. The forecast allows investors in exchange traded U.S. Treasury funds (TLT) (TBT), total return bond funds (BOND), municipal bonds (NUV) and exchange traded mortgage funds (REM) to assess likely total returns over the next 120 months. Treasury-related exchange traded funds affected by the forward rates include:

Top Performing Stocks To Watch Right Now: Ormat Technologies, Inc.(ORA)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of U.S. Geothermal back in positive territory while potential peer mid cap Calpine Corporation (NYSE: CPN) is underperforming and Ormat Technologies, Inc (NYSE: ORA) has been taking off for two years:

Top Performing Stocks To Watch Right Now: TransUnion(TRU)

Advisors’ Opinion:

  • [By JJ Kinahan]

    Ready To Shop? A highlight this coming week is Black Friday, and recent data hint that shoppers might be ready. A record 195.9 million consumers now have access to revolving credit such as bank-issued and private label credit cards, TransUnion (NYSE: TRU) said in a recent press release. This is the highest level of revolving credit access since TRU began measuring the variable and is greater than the 192.6 million consumers who had access to such credit products in Q3 2016. “The third quarter of 2017 exhibited a lending market that continued to operate in a stable manner, with consumers continuing to gain access to credit and take advantage of that access,” said Ezra Becker, senior vice president and head of research and consulting for TransUnion, in the press release. “However, we are beginning to see a slowdown in originations, which may be a signal of saturation in the lower-risk credit tiers and some pull-back in lender risk appetite in the higher-risk tiers.” Still, Becker predicted a “robust holiday shopping season.”

Top Performing Stocks To Watch Right Now: Bank of Hawaii Corporation(BOH)

Advisors’ Opinion:

  • [By Monica Gerson]

    Bank of Hawaii Corporation (NYSE: BOH) is expected to report its quarterly earnings at $0.99 per share on revenue of $149.88 million.

    Zions Bancorporation (NASDAQ: ZION) is projected to post its quarterly earnings at $0.39 per share on revenue of $576.49 million.